- Home
- EPSM vs PASG Comparison
EPSM vs PASG Comparison
Compare EPSM & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | PASG |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | China | United States |
| Employees | 17 | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 15.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EPSM | PASG |
|---|---|---|
| Price | $1.51 | $4.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 39.7K | 33.2K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $3.29 |
| 52 Week High | $155.00 | $20.00 |
Technical Indicators
Market Signals| Indicator | EPSM | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 39.21 |
| Support Level | $1.29 | $4.25 |
| Resistance Level | $1.53 | $5.04 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 100.00 | 10.45 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.